Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Poolbeg Pharma Ltd. ( (GB:POLB) ) has provided an announcement.
Poolbeg Pharma has announced its participation as the lead business partner in the RISE programme, a groundbreaking research initiative into cancer immunotherapy-induced Cytokine Release Syndrome (CRS), led by The University of Manchester and The Christie NHS Foundation Trust. Supported by a £3.4 million grant from the Medical Research Council, the programme will feature the POLB 001 TOPICAL trial and aims to enhance the safety and delivery of advanced cancer immunotherapies. This collaboration, involving partners like Johnson & Johnson, reflects the growing recognition of the need to manage CRS, which is a significant barrier to the broader adoption of these therapies.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on transforming the cancer immunotherapy field. The company’s lead asset, POLB 001, aims to make cancer immunotherapies safer by preventing Cytokine Release Syndrome (CRS), a severe side effect, potentially expanding the administration of these treatments beyond specialist centers. Poolbeg is also developing a patient-friendly therapy for obesity with an oral encapsulated GLP-1, targeting large markets and addressing critical unmet medical needs.
Average Trading Volume: 1,249,167
Technical Sentiment Signal: Hold
Current Market Cap: £25.45M
See more data about POLB stock on TipRanks’ Stock Analysis page.